immunotherapy resistance

Unraveling the S1P-TREM2 Axis: A Novel Ferroptosis-Resistance Mechanism Driving Immunosuppressive Neutrophils and Tumour Progression in Hepatocellular Carcinoma

By MedXY 09/12/2026

This study reveals how the S1P-TREM2-NRF2 signaling pathway protects tumor-associated neutrophils from ferroptosis, sustaining immunosuppression and promoting hepatocellular carcinoma progression, offering new therapeutic avenues.

Gastroenterology news Oncology

Extracellular Vesicles as Liquid Biopsy Biomarkers Predicting Immune Checkpoint Therapy Resistance in Hepatocellular Carcinoma

By MedXY 08/09/2026

Circulating extracellular vesicles carrying PD-1, PD-L1, and CTLA-4 can non-invasively predict responses and early resistance to immune checkpoint inhibitors in advanced hepatocellular carcinoma, improving patient stratification and management.

Gastroenterology news Oncology

A Stromal CTHRC1 Biomarker Framework May Identify Colorectal Cancers With Poor Prognosis and Limited Immunotherapy Benefit

By MedXY 05/10/2026

A large multiomic colorectal cancer study identifies CTHRC1-positive fibroblasts as a stromal biomarker linked to TGF-beta activity, adverse outcomes, and reduced checkpoint inhibitor benefit across both MSI and MSS disease.

Hematology-Oncology news Oncology

When Targeting Becomes a Double-Edged Sword: How Loss of GPRC5D May Fuel Multiple Myeloma Progression

By MedXY 04/12/2026

Researchers discovered that loss of GPRC5D, a key immunotherapy target in multiple myeloma, not only confers resistance to targeted therapies but actively promotes cancer cell proliferation and competitive fitness—creating a therapeutic paradox that warrants careful clinical monitoring.

news Oncology Urology

AHR Inhibition with IK-175: A New Frontier in Overcoming Checkpoint Resistance in Urothelial Carcinoma

By MedXY 01/11/2026

This Phase 1/1b study demonstrates that IK-175, an oral AHR inhibitor, is safe and clinically active in PD-1-refractory urothelial carcinoma, showing target engagement and preliminary efficacy both as monotherapy and in combination with nivolumab.

Clinical Updates news Oncology Specialties

Overcoming PD-1 Inhibitor Resistance: Six Emerging Strategies from the 2025 ASCO Annual Meeting

By MedXY 08/06/2025

PD-1 inhibitor resistance is a major hurdle in cancer immunotherapy. Six leading combination strategies—including chemotherapy, anti-angiogenic agents, radiotherapy, novel checkpoint inhibitors, microbiome modulation, and ADCs—offer new hope for overcoming resistance and improving patient outcomes.